QIAGEN Announces Completion of Synthetic Share Repurchase Plan

QIAGEN N.V. announced on December 18, 2025, the details for the completion of a synthetic share repurchase plan, valued at approximately $500 million. This plan, approved by shareholders in June 2025, combines a direct capital repayment with a reverse stock split. The transaction is set to be completed on January 7, 2026. Shareholders will receive a capital repayment of $2.29 per pre-consolidation share, and every 20 shares will be consolidated into 19 shares. This initiative is expected to reduce the number of outstanding shares by approximately 5% and enhance earnings per share (EPS). With this repurchase, QIAGEN will have returned at least $1 billion to shareholders by the end of 2028, ahead of schedule. The company is also considering additional measures to increase shareholder returns in 2026 and beyond. The last day of trading for pre-split shares on the NYSE and Frankfurt Stock Exchange is January 7, 2026, with consolidated shares trading under the same ticker symbols starting January 8, 2026.